<DOC>
	<DOCNO>NCT01500486</DOCNO>
	<brief_summary>This study conduct Europe . The aim study evaluate ease injection growth hormone patient use Norditropin NordiFlex® NordiFlex PenMate™ . Convenience tolerability NordiFlex PenMate™ - automatic injection needle hide device - also evaluate .</brief_summary>
	<brief_title>Observational Study Norditropin NordiFlex® With NordiFlex PenMate™</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>After physician decision make use Norditropin Nordiflex® growth hormone therapy accordance locally approve labelling , subject eligible study , include newly diagnose subject never receive growth hormone therapy subject treat growth hormone product ( exclusion patient receive previously Norditropin Nordiflex® ) need switch new product . The selection subject discretion individual physician Contraindications Norditropin® growth hormone therapy Subjects receive Norditropin NordiFlex® prior study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>